Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis

Journal of Molecular Medicine

Volumn 90, Issue 1, 2012, Pages 25-30

  Smink, Jeske J ^a,b   Tunn, Per Ulf ^c   Leutz, Achim ^a,b,d  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

C EBP ; Giant cell tumor; MafB; MTOR; Osteoclast

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TRANSCRIPTION FACTOR MAFB;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCLASTOMA; OSTEOLYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; BONE RESORPTION; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELLS, CULTURED; GIANT CELL TUMOR OF BONE; HUMANS; MAFB TRANSCRIPTION FACTOR; OSTEOCLASTS; PROTEIN TRANSPORT; SIROLIMUS;

EID: 84857371374     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0823-6     Document Type: Article

References (25)

1. Thomas DM, Skubitz KM (2009) Giant cell tumour of bone. Curr Opin Oncol 21:338-344
2. Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, Hogendoorn P, Kroep J, Wass J, Athanasou N (2010) Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 10:462-469
3. Chang SS, Suratwala SJ, Jung KM, Doppelt JD, Zhang HZ, Blaine TA, Kim TW, Winchester RJ, Lee FY (2004) Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. Clin Orthop Relat Res 426:103-109 (Pubitemid 39167115)
4. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S (2010) Denosumab in patients with giant-cell tumour of bone: an openlabel, phase 2 study. Lancet Oncol 11:275-280
5. Novack DV, Teitelbaum SL (2008) The osteoclast: friend or foe? Annu Rev Pathol 3:457-484 (Pubitemid 351488289)
6. Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28:370-377 (Pubitemid 32385408)
7. Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM (2000) Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15:640-649 (Pubitemid 30174018)
8. Huang L, Xu J, Wood DJ, Zheng MH (2000) Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156:761-767 (Pubitemid 30626932)
9. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X (2002) RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 117:210-216 (Pubitemid 34823661)
10. Morgan T, Atkins GJ, Trivett MK, Johnson SA, Kansara M, Schlicht SL, Slavin JL, Simmons P, Dickinson I, Powell G, Choong PF, Holloway AJ, Thomas DM (2005) Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 167:117-128 (Pubitemid 40884775)
11. Smink JJ, Begay V, Schoenmaker T, Sterneck E, deVries TJ, Leutz A (2009) Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB. EMBO J 28:1769-1781
12. Smink JJ, Leutz A (2010) Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases. J Mol Med 88:227-233
13. Wethmar K, Begay V, Smink JJ, Zaragoza K, Wiesenthal V, Dorken B, Calkhoven CF, Leutz A (2010) C/EBPbetaDeltauORF mice-a genetic model for uORF-mediated translational control in mammals. Genes Dev 24:15-20
14. Wethmar K, Smink JJ, Leutz A (2010) Upstream open reading frames: molecular switches in (patho)physiology. Bioessays 32 (10):885-893
15. Kim K, Kim JH, Lee J, Jin HM, Kook H, Kim KK, Lee SY, Kim N (2007) MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 109:3253-3259 (Pubitemid 46572510)
16. Calkhoven CF, Muller C, Leutz A (2000) Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev 14:1920-1932 (Pubitemid 30639525)
17. Corradetti MN, Guan KL (2006) Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25:6347-6360 (Pubitemid 44582281)
18. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S, Lietz A, Leutz A, Dorken B (2005) A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas. Blood 106:1801-1807 (Pubitemid 41208597)
19. Ng PK, Tsui SK, Lau CP, Wong CH, Wong WH, Huang L, Kumta SM (2010) CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression. J Cell Biochem 110:438-446
20. Werner M (2006) Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 30:484-489 (Pubitemid 44900556)
21. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N (2008) NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 22:176-185
22. Boyce BF, Xing L, Yao Z, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK (2006) Future anti-catabolic therapeutic targets in bone disease. Ann N Y Acad Sci 1068:447-457 (Pubitemid 43824173)
23. Berenson JR, Yellin O (2008) New drugs in multiple myeloma. Curr Opin Support Palliat Care 2:204-210
24. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314-5322 (Pubitemid 46206985)
25. Wan X, Mendoza A, Khanna C, Helman LJ (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65:2406-2411 (Pubitemid 40490152)